NCT03470935

Brief Summary

Brest cancer is the most common cancer in women in France with 52.000 new cases diagnosed in 2010 including nearly 6.000 women younger than 40. The improvement of the fertility conservation of cancer patients is one of the goals put forward by the french Cancer Plan (Objective 8.1). The issue of fertility after a breast cancer is a frequently raised subjects by the concerned couples today. The improvement in prognosis due to therapeutic advances combined with the increasing age of the first pregnancy and in the recomposed couples bring number of young women between 35 and 40 years followed for breast cancer today to raise these questions with their oncologists. Young women have a greater risk to develop agressive tumors requiring a mulitimodal treatment whose general and gonadic side effects can be important and permanently impact the reproductive capacity. At the time of diagnosis, almost 50% of these young patients report that they want to consider a later pregnancy but no data are available on the evolution of this wish over time although it is known that anti-cancer treatments have a serious impact on future possibilities of pregnancy(s). The sequential chemotherapy regimen prescribed in adjuvant or neo-adjuvant situation includes intercaling agents (antracyclines) and an alkylating agent (cyclophosphamide) partially responsible for subsequent fertility disorders. In addition, a chemotherapy-induced amenorrhea (CAI) occurs in 50 to 80% of women according to the studies, the latter is sometines definitive and sequellar of treatment. However, few data describe the time of recovery of menstrual cycles in women with CAI and subsequent impact of fertility. The aim of this study is to evaluate the impact of cancer diagnosis and treatment on the wishes of fertility before and after the management of cancer of the patients in question, on the recovery of menstrual cycles and the quality of sexual life of these patients. The investigators hope to improve the pre-therapeutic evaluation of women wishing to implement measures to preserve fertility, to assist women wishing to consider this type of project after cytotoxic treatments and accompany women suffering from a change in self-image that has an impact on their quality of life. These results could help to sensitize the doctors to the difficulties encountered by young women and to improve and/or to strengthen the global and adapted care of these patients.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
60

participants targeted

Target at P25-P50 for all trials

Timeline
Completed

Started Sep 2017

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

September 15, 2017

Completed
1 month until next milestone

First Submitted

Initial submission to the registry

October 23, 2017

Completed
5 months until next milestone

First Posted

Study publicly available on registry

March 20, 2018

Completed
6 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

September 30, 2018

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

September 30, 2018

Completed
Last Updated

January 16, 2019

Status Verified

January 1, 2019

Enrollment Period

1 year

First QC Date

October 23, 2017

Last Update Submit

January 15, 2019

Conditions

Keywords

breast canceryoung women

Outcome Measures

Primary Outcomes (1)

  • Describe the impact of diagnosis and the breast cancer care on fertility in patients younger than 40 years

    measurement of menstrual cycles

    through study completion, an average of 1 year

Eligibility Criteria

Age18 Years - 40 Years
Sexfemale
Healthy VolunteersNo
Age GroupsAdult (18-64)
Sampling MethodNon-Probability Sample
Study Population

patients aged between 18 and 40 years at the time of diagnosis of non-metastatic breast cancer and having completed their radiotherapy and/or chemotherapy treatment(s) for at least 3 months

You may qualify if:

  • Patient with non-metastatic breast cancer ;
  • Age of patient between 18 and 40 years at histological diagnosis ;
  • Patient treated with neoadjuvant or adjuvant chemotherapy with or without radiotherapy or endocrine therapy ;
  • Patient who have completed their chemotherapy and/or radiotherapy treatment for at least 3 months at the time of questionnaire dispatch ;
  • Patient informed of the study (patient must have received the informed consent document and doesn't opposed to it) and who answered to the specific questionnaire of the study ;

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Centre investigateur CARIO-HPCA

Plérin, 22190, France

Location

MeSH Terms

Conditions

Breast Neoplasms

Condition Hierarchy (Ancestors)

Neoplasms by SiteNeoplasmsBreast DiseasesSkin DiseasesSkin and Connective Tissue Diseases

Study Officials

  • Jérôme Martin-Babau

    Hôpital Privé des Côtes d'Armor (HPCA)

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
observational
Observational Model
COHORT
Time Perspective
RETROSPECTIVE
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Principal Investigator

Study Record Dates

First Submitted

October 23, 2017

First Posted

March 20, 2018

Study Start

September 15, 2017

Primary Completion

September 30, 2018

Study Completion

September 30, 2018

Last Updated

January 16, 2019

Record last verified: 2019-01

Locations